Company Overview - Cardinal Health is a global healthcare services and products distributor, serving hospitals, healthcare providers, pharmacies, and manufacturers [11] - The company operates under three segments: Pharmaceutical and Specialty Solutions, Global Medical Products and Distribution (GMPD), and Other [11] Investment Insights - Cardinal Health has a Zacks Rank of 3 (Hold) and a VGM Score of B, indicating a moderate investment outlook [11] - The company has a Momentum Style Score of B, with shares increasing by 5.6% over the past four weeks [12] - Eight analysts have revised their earnings estimates upwards for fiscal 2025, with the Zacks Consensus Estimate rising by $0.18 to $8.12 per share [12] - Cardinal Health has an average earnings surprise of 10.3%, suggesting potential for positive performance [12]

Henry Schein (HSIC) 2025 Conference May 14, 2025 01:00 PM ET Speaker0 Welcome to day two of the BofA Healthcare Conference. My name is Alan Lutz. I run Healthcare Tech and Distribution here at BofA. We are very excited to welcome Henry Schein. We have CFO Ron South. Ron, thank you for joining us. Speaker1 Thank you, Al. Speaker0 I wanted to start talking about recent dental trends that you're seeing in the market. So if we go back to the call from, I believe, last week, talked about January, some weather re ...

Owens & Minor (OMI) Q1 2025 Earnings Call May 08, 2025 08:00 AM ET Company Participants Jackie Marcus - Senior Managing DirectorEdward A. Pesicka - President, CEO & DirectorJon Leon - EVP & CFOJohn Stansel - VP - Equity ResearchAhmed Muhammad - AssociateKevin Caliendo - Managing Director Conference Call Participants Luismario Higuera - AnalystEric Coldwell - Senior Research Analyst Operator Good day, and thank you for standing by. Welcome to the Owens and Minor First Quarter twenty twenty five Earnings Conf ...

Owens & Minor (OMI) Q1 2025 Earnings Call May 08, 2025 08:00 AM ET Speaker0 Good day, and thank you for standing by. Welcome to the Owens and Minor First Quarter twenty twenty five Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question and answer Thank you. And please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Jackie Marcus, Investo ...

Core Viewpoint - Henry Schein, Inc. (HSIC) reported adjusted earnings per share (EPS) of $1.15 for Q1 2025, reflecting a 4.5% increase year-over-year and exceeding the Zacks Consensus Estimate by 3.6% [1][12] Financial Performance - The company recorded a GAAP EPS of 88 cents, up from 72 cents in the same quarter last year [2] - Q1 revenues were $3.17 billion, a slight decline of 0.1% year-over-year, and fell short of the Zacks Consensus Estimate by 1.8% [3] - Constant currency total net sales increased by 1.4%, while excluding PPE and COVID-19 test kits, sales growth was 2% year-over-year [3] Segment Analysis - Global Distribution and Value-Added Services segment sales decreased by 0.7% to $2.68 billion, with a 0.8% increase in constant currencies [4] - Global Dental Distribution merchandise sales rose by 0.4% in constant currencies, while equipment sales fell by 2.4% due to sales deferrals [5] - Global Medical Distribution sales increased by 3% in constant currencies, driven by higher patient traffic and growth from acquisitions [5] - Global Specialty Products segment sales totaled $367 million, up 2% on a reported basis [6] - Global Technology segment sales reached $162 million, reflecting a 2.9% increase on a reported basis [7] Margin and Liquidity - Gross profit for the quarter was $1.00 billion, a 1.2% decrease year-over-year, with gross margin contracting to 31.6% [8] - SG&A expenses decreased by 6.7% to $738 million, while adjusted operating profit rose by 18.6% to $262 million [8] - The company ended Q1 2025 with cash and cash equivalents of $127 million, up from $122 million at the end of Q4 2024 [9] Share Repurchase and Guidance - HSIC repurchased approximately 2.3 million shares at an average price of $71.58, totaling around $161 million, with $718 million available for future repurchases [10] - The company maintained its adjusted EPS forecast for 2025 in the range of $4.80-$4.94, indicating 1-4% growth from 2024 [11] Strategic Outlook - HSIC is advancing its BOLD+1 Strategic Plan for 2025 to 2027, focusing on operational efficiency, enhancing customer experience, and expanding its digital solutions [13]

Henry Schein (HSIC) Q1 2025 Earnings Call May 05, 2025 08:00 AM ET Company Participants Graham Stanley - VP of Investor Relations & Strategic Finance Project OfficerStanley Bergman - Chairman and CEORonald South - Senior VP & CFOJonathan Block - Managing DirectorMichael Petusky - Managing DirectorJohn Stansel - VP - Equity Research Conference Call Participants Jason Bednar - Senior Research AnalystJeffrey Johnson - Senior Research AnalystElizabeth Anderson - Senior Managing Director & Research AnalystAllen ...

1 Cautionary Note Regarding Forward-Looking Statements and Use of Non-GAAP Financial Information Q1 2025 Earnings Conference Call In accordance with the "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995, we provide the following cautionary remarks regarding important factors that, among others, could cause future results to differ materially from the forward-looking statements, expectations and assumptions expressed or implied herein. Financial Results & Outlook All forward-lo ...